Altimmune (ALT) EBITDA (2010 - 2026)
Altimmune (ALT) reported EBITDA of -$22.9 million for Q1 2026, down 16.6% year-over-year from -$27.4 million in Q1 2025, and up 16.18% quarter-over-quarter from -$27.3 million in Q4 2025.
Altimmune (ALT) EBITDA (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of EBITDA data on file, last reported at -$22.9 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$22.9 million, down 16.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$91.3 million (down 1.35% YoY), and the FY2025 annual result was -$88.0 million, up 7.35% from the prior year.
- EBITDA rose to -$22.9 million in Q1 2026 per ALT's latest filing, from -$27.3 million in the prior quarter.
- Over five years, EBITDA peaked at -$16.1 million in Q2 2023 and troughed at -$31.5 million in Q4 2023.
- A 5-year average of -$22.3 million and a median of -$22.2 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2024: EBITDA grew 29.4% in 2022, then sank 52.86% in 2024.
- A 5-year view of EBITDA shows it stood at -$21.6 million in 2022, then slumped by 46.04% to -$31.5 million in 2023, then increased by 26.06% to -$23.3 million in 2024, then slipped by 17.0% to -$27.3 million in 2025, then climbed by 16.18% to -$22.9 million in 2026.
- Business Quant data shows ALT's EBITDA at -$22.9 million in Q1 2026, -$27.3 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -22.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.86 Mn |
| Dec 31, 2025 | -27.27 Mn |
| Sep 30, 2025 | -18.99 Mn |
| Jun 30, 2025 | -22.18 Mn |
| Mar 31, 2025 | -19.61 Mn |
| Dec 31, 2024 | -23.31 Mn |
| Sep 30, 2024 | -22.50 Mn |
| Jun 30, 2024 | -24.67 Mn |
| Mar 31, 2024 | -24.55 Mn |
| Dec 31, 2023 | -31.52 Mn |
| Sep 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -16.14 Mn |
| Mar 31, 2023 | -19.95 Mn |
| Dec 31, 2022 | -21.58 Mn |
| Sep 30, 2022 | -23.66 Mn |
| Jun 30, 2022 | -20.23 Mn |
| Mar 31, 2022 | -19.43 Mn |
| Dec 31, 2021 | -23.89 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |